Genmab — Maj 2020
-
Jeg tænker, du skæver til de amerikanske indeks, men der er virkelig stærke kræfter, der trækker. Jeg fornemmer, der er noget stort på vej. Nogen ved noget, og det presser forventningerne op. Det var store handler, som blev gennemført. Aktien kan meget vel fortsætte op for at køre mindre sælgere over. Men der kommer snart noget gevinst hjemtagning
-
Futures er ret røde.. Måske vi ser et stort hak ned i morgen som følge af de store stigninger?
-
Tilfældingfandt den her fra JNJs 2020Q1-præsentation (14.04) af deres "Selected late stage development/registration" og "Selected NME (New Molecular Entity) pipeline". Amivantamab (JNJ-6372) og de 2 andre GEN bsMabs allerede fremhævet som potentielle blockbusters (JNJ-7564/7957) optræder alle under kolonneoverskriften "NME planned filings 20-23". Der har sikkert været linket til den før, men hva pokker...
-
-
God morgen.
-
dara vs Sarclisa (GEN): https://www.proinvestor.com/debat/84218#84220
-
Nyt studie med Ofatumumab. ( ARTIOS ) . Ved ikke om det har været postet. https://www.clinicaltrials.gov/ct2/show/NCT04353492?term=Ofatumumab&draw=1&rank=4
-
From BioNTech SE (BNTX) Q1 2020 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/05/13/biontech-se-bntx-q1-2020-earnings-call-transcript.aspx
-
"For our next-generation checkpoint-immune modulatory program partnered with Genmab, the ongoing trial with BNT311, the PD-L1x4-1BB dual body, continues to advance rapidly, as the expansion cohort has been initiated. Data from this Phase 1/2 trial in multiple solid tumors is expected in the second half of this year. We expect the updates to include dose escalation and safety data from the trial. We are excited about this program.
-
We believe it has broad potential in a range of solid tumors, including those where checkpoint therapy is currently established but also more difficult tumors where first-generation checkpoint inhibitors have not been as successful. This bispecific antibody has outperformed conventional checkpoint inhibitors in preclinical animal models. We have seen strong evidence in the preclinical setting of its ability to amplify the effect of our vaccines as well."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind